Objective: A systematic review and a meta-analysis were carried out in order to summarize the current published studies and to evaluate LINE-1 hypomethylation in blood and other tissues as an epigenetic marker for cancer risk.
Introduction
Epigenetic alterations, heritable DNA modifications that do not involve changes in the DNA sequence, are associated with changes in gene expression and are important in maintaining genomic stability [1] . Among epigenetic mechanisms, DNA methylation is the most commonly studied and involved in various biological processes including cancer [2] [3] [4] [5] . Global hypomethylation, an overall genome-wide reduction in DNA methylation content, is associated with genomic instability and an increased number of mutational events [6] . Genomic DNA hypomethylation is likely to result from demethylation in repetitive elements, which account for about 55% of the human genome and determine gene regulation and genomic stability [7, 8] . Long Interspersed Nucleotide Element 1 (LINE-1) and Alu repetitive elements are major constituents of interspersed DNA repeats. Due to their high occurrence throughout the genome, methylation in repetitive elements have been shown to correlate with global genomic DNA methylation content and demethylation has been associated with genome instability and chromosomal aberrations. Thus, LINE-1 and Alu have been used as global surrogate markers for estimating the genomic DNA methylation level in cancer tissues [6, [9] [10] and in peripheral blood leukocytes [11] . LINE-1 hypomethylation was observed in several types of cancer [12] [13] [14] and was associated with a poor prognosis [15] . In a meta-analysis [11] , global DNA hypomethylation in peripheral blood leukocytes was associated with increased cancer risk. Another meta-analysis, investigating genome-wide DNA methylation in peripheral blood DNA and cancer risk, reports a significant inverse association between genomic 5-methylcytosine levels and cancer risk, but no overall risk association using surrogates for genomic methylation, including methylation at the LINE-1 and Alu repetitive elements was found [16] . The aim of the present study was to carry out a more comprehensive systematic review and a meta-analysis in order to summarize the current published studies and to evaluate LINE-1 hypomethylation in blood and other tissues as an epigenetic marker for cancer risk.
Methods

Search strategy and selection criteria
A systematic literature search in the Medline database, using PubMed, was carried out for epidemiological studies, published before March 2014, investigating the association between LINE-1 hypomethylation and cancer risk. The searches were limited to studies written in English; abstracts and unpublished studies were not included. Literature search was conducted independently by two Authors. The following selection criteria were used to search articles and abstracts: (''cancer'' or ''tumor'' or ''carcinoma'') AND (''LINE-1'' or ''Long Interspersed Element-1'' or ''global'') AND (''hypomethylation'' or ''methylation''). Moreover, the reference lists from selected articles were checked to search for further relevant studies. No studies were excluded a priori for weakness of design or data quality. Articles were included in the quantitative analysis only if they satisfied the following criteria: (1) case-control or cohort study designs; and (2) studies that reported mean values and standard deviations (SD) of DNA methylation level in cancer patients and in control group. Furthermore exclusion criteria were as follows: (1) the study reporting only results as median of the methylation levels or through graphic display, or 95% confidence intervals (CIs) with adjusted odds ratios (OR) or relative risks for cancer risk in subjects with the lowest level of global DNA methylation (tertile, quartile or decile) compared to group with the highest level, (2) the study reporting only gene-specific DNA methylation analysis, and (3) review articles.
Where there were missing data or additional information were required, study Authors were contacted by email.
The preferred reporting items for systematic reviews and metaanalysis (PRISMA) guidelines for the conduct of meta-analysis were followed [17] .
Data collection and extraction
Two of the Authors independently reviewed all the eligible studies and abstracted the following information in a standard format: first Author's last name, year of publication, country where the study was performed, study design, cancer sites and types, sample type, experimental methods to measure global DNA methylation levels, number of cases and controls, mean values and SD of global DNA methylation levels for each group and main results. 
Statistical Analysis
All data were analyzed using the REVIEW MANAGER 5.2 software provided by the Cochrane Collaboration (http://ims. cochrane.org/revman).
The random-effects model was used to estimate weighted mean differences (MDs) with 95% CI [18] and thus, no adjustment for environmental effects was taken into account. Furthermore, subgroup analyses were conducted by sample type (tissue or blood samples), by sample source (fresh tissue or formalin-fixed, paraffinembedded, FFPE tissue), by cancer types (colorectal, stomach, hepatocellular), and by assays used to measure global DNA methylation levels. Forest plots were generated to illustrate the study-specific effect sizes along with a 95% CI. Heterogeneity across studies, was measured using the Q-test based on the x2 statistic, considering significant statistical heterogeneity as p,0.1. As Cochran's test only indicates the presence of heterogeneity and not its magnitude, we also reported the I 2 statistic, which estimates the percentage of outcome variability that can be attributed to heterogeneity across studies. An I 2 value of 0% denotes no observed heterogeneity, whereas, 25% is ''low'', 50% is ''moderate'' and 75% is ''high'' heterogeneity [19] . We also estimated the between-study variance using tau-squared (t 2 ) statistic [20] .
To determine the presence of publication bias, the symmetry of the funnel plots in which mean differences were plotted against their corresponding standard errors were assessed. 
Results
Data extraction
The detailed steps of the systematic review and meta-analysis process are given as a PRISMA flow chart in Figure 1 . A total of 324 articles were retrieved from the database, one article was added through manual searching with reference list and thus 46 papers, published between 2004 and 2014, were included in the systematic review and summarized in Table 1 by cancer site or type.
Data characteristics and quality assessment
A total of 18 studies were from Asian countries (40%), 13 from European countries (28%), 13 from USA (28%) and 1 from Argentina and from Egypt (2%, each).
Thirty-eight retrospective longitudinal studies compared LINE-1 methylation levels between cancer patients and healthy subjects or normal adjacent tissues in cancer patients. Eight prospective longitudinal studies analysed LINE-1 methylation levels in cohorts of cancer patients, in relation to the life expectancy, the outcome of the disease or the malignancy of the tumor, identifying the role of LINE-1 hypomethylation as a biomarker of poor prognosis in cancer patients [15, [21] [22] [23] [24] [25] [26] [27] .
In 41 studies LINE-1 methylation levels were evaluated both in tumor and in healthy controls tissues, and in the remaining 5 studies only in cancer patients.
Overall, the studies detected LINE-1 methylation levels in 15332 samples: 8103 from cancer patients (4679 tissue samples, 3276 blood samples ,72 oral rinses and 76 bone marrow plasma cells) and 7136 control samples (6277 from healthy subjects and 859 from normal adjacent tissues in cancer patients).
Regarding the experimental methods to measure LINE-1 methylation levels, the ''gold standard'' method, used in 63% of studies, was the pyrosequencing of bisulphite converted DNA. Furthermore, 9 studies used combined bisulphite restriction analysis of LINE-1 (COBRA LINE-1) and 8 studies used other methods, i.e. sequencing, real-time PCR, AQAMA PCR, COM-PARE methylation assay, MulticolorMethyLight Assay and MS-MLPA. The most frequent tumor type in study was colorectal cancer analyzed in eight studies [15, 21, [28] [29] [30] [31] [32] [33] , followed by seven studies that evaluated methylation level in gastric cancer [23, 27, 32, [34] [35] [36] [37] , five in hepatocellular carcinoma [25, [38] [39] [40] [41] , four in bladder cancer [1, 14, 42, 43] and head and neck carcinoma [10, [44] [45] [46] , two in lung cancer [47, 48] and breast cancer [24, 49] , and single studies assessed methylation levels in renal cell cancer [50] , prostate cancer [51] , neuroendocrine tumor [52] , ovarian cancer [53] , thyroid cancer [54] , esophageal cancer [26] , cervix cancer [55] , endometrial cancer [32] , skin melanoma [22] , testicular cancer [56] , leukemia [57] , multiple myeloma [58] , paraganglioma [59] , fibrolamellar carcinoma [60] and gastrointestinal [61] . Four studies evaluated methylation level in several cancer sites [13, 28, 29, 32] . With regard to the assay method, pyrosequencing was used in 29 studies, followed by COBRA in 9 studies, RealTime PCR and AQAMA-PCR in 2 studies. MulticolorMethyLight Assay, MS-MLP, COMPARE and QUBRA were adopted in single study each.
Meta-analysis
Of the 46 selected papers, 14 reported means and SD of DNA methylation levels. In addition, means and SDs were independently calculated using data from 2 articles and, among Authors contacted for missing data, 3 responded to the email requests and data were added in the analysis [30, 50, 56] . Thus, 19 unique articles were included in the quantitative analysis. Furthermore, two papers by Antelo et al. [28] and by Pavicic et al. [32] , reported data from different cancer types and thus, they were separated in 4 and 8 sub-studies, respectively (Table 1) .
A total of 6107 samples were included in the analysis: 2554 from cancer patients (1127 tissue samples and 1427 blood samples) and 3553 control samples (2811 from healthy subjects and 742 from normal adjacent tissues in cancer patients).
LINE-1 methylation levels were significantly lower in cancer patients than in control samples (MD: 26.40, 95% CI: 27.71, 2 5.09; p,0.001). However, heterogeneity between studies was significantly high (I 2 = 99%) (Figure 2) , thus, subgroup analysis based on sample type (tissue or blood samples) was performed. A subgroup analysis by sample source was conducted. LINE-1 methylation levels were significantly lower in cancer patients than in control samples in fresh and/or frozen tissue (MD 28.19; 95% CI: 210.54, 25.84; p,0.001) and in FFPE tissue (MD: 26.96; 95% CI: 29.73, 24.20; p,0.001). Heterogeneity between studies, in the two subgroups was significantly high (I 2 = 98% and 96% respectively) (Figure 3) .
Furthermore, a subgroup analysis by specific cancer types, for colorectal, hepatocellular and gastric cancer, was conducted. LINE-1 methylation levels were significantly lower in colorectal and gastric cancer patients than in control samples (MD: 28.33; 95% CI: 210.56, 26.10; p,0.001 and MD: 25.75; 95% CI: 2 7.75, 23.74; p,0.001). No difference of LINE-1 methylation levels in blood leukocytes was observed for hepatocellular cancer (MD: 25.76; 95% CI: 212.03, +0.51; p = 0.23). Heterogeneity between studies, in colorectal and hepatocellular subgroups was significantly high (I 2 = 96%), and moderately high in the gastric subgroups (I 2 = 66%) ( Figure 4) . A subgroup analysis by assays used to measure the methylation levels, and particularly, between the two commonly used techniques, pyrosequencing and COBRA LINE-1, was performed. The MDs for pyrosequencing and COBRA LINE-1 subgroups were -7.33 (95% CI: 29.06, 25.59; p,0.001) and 25.75 (95% CI: 27.13, 24.37; p = 0.03), respectively. Heterogeneity between studies and in the pyrosequencing subgroup was significantly high (I 2 = 100%), and moderately high in the COBRA subgroup (I 2 = 63%) ( Figure 5) . A subgroup analysis by sample type, particularly tissue samples, and assay method was conducted. The MDs in the subgroups of studies which detected LINE-1 methylation levels in tissue samples through pyrosequencing and COBRA LINE-1, were 210.42 (95% CI: 212.93, 27.91; p,0.001) and 25.12 (95% CI: 26.33, 23.91; p = 0.10), respectively. Heterogeneity between studies and in the pyrosequencing subgroup was significantly high (I 2 = 97%), moderately high in COBRA LINE-1 subgroup (I 2 = 56%) ( Figure 6) . Stratification among studies which detected LINE-1 methylation in blood samples was not performed due to the paucity of studies.
The funnel plots indicate small to moderate asymmetry, suggesting that publication bias cannot be completely excluded as a factor of influence on the present meta-analysis (Figures 7-12 ). 
Discussion
The low level of DNA methylation in tumors compared with DNA methylation level in their normal-tissue counterparts was one of the first epigenetic alterations to be found in human cancer [62] . The loss of methylation is mainly due to hypomethylation of repetitive DNA sequences and LINE-1 elements are typically heavily methylated in normal tissues, while LINE-1 hypomethylation has been reported in cancer tissues. Furthermore, Liao et al. [50] reported that LINE-1 methylation levels, measured in leukocyte DNA, were significantly higher in renal cancer patients than in healthy subjects.
Two recent meta-analyses were conducted in order to estimate overall cancer risk according to global DNA hypomethylation in blood leukocytes. The meta-analysis by Woo and Kim [11] reports that global DNA hypomethylation of blood leukocytes was associated with increased cancer risk, although the association varied by the experimental methods used (% 5-methylcytosine method, LINE-1 with pyrosequencing and methyl acceptance assay), the region of DNA targeted and the cancer type. An updated meta-analysis performed by Brennan and Flanagan [16] indicates a significant inverse association between genomic 5-methylcytosine levels and cancer risk (OR = 3.65; 1.20-6.09), but no overall risk association for studies using surrogates for genomic methylation, including methylation at the LINE-1 repetitive element (OR = 1.24; 0.76-1.72). Notably, the previous two meta-analyses included studies reporting association analysis between blood methylation levels and cancer risk but did not evaluate studies reporting differences in mean methylation levels in blood and in other tissues. The present meta-analysis of recent reports was conducted including studies reporting methylation levels in blood and in other tissues. This meta-analysis concerned 19 unique articles, but since two articles comprised more than one study conducted on different patient populations, altogether there were 29 non-unique studies included. On a total of 2554 samples from cancer patients and 3553 control samples, this meta-analysis reports that mean methylation levels in cancer patients were significantly 6.4% lower than in control samples.
The association between cancer risk and global DNA methylation has been mostly investigated in blood samples, because harvesting tumor tissue is invasive and cannot be routinely performed. However, several studies have reported that methylation of repetitive elements is tissue specific, most variable in tumor tissue, and is not correlated between tumor and blood [63] [64] [65] . Consistently, evidence reveals that genomic hypomethylation in tumor and normal adjacent tissue of bladder and colon cancer was not detectable in blood [43, 66] , suggesting that hypomethylation is restricted to the disease affected tissue. Interestingly, in the present meta-analysis the significant difference in mean methylation levels was confirmed only in tissue samples, both fresh/ frozen or FFPE specimens, but not in blood samples. Furthermore, the meta-analysis provided sufficient evidence that LINE-1 hypomethylation, significantly increases in colorectal and gastric cancer. On the contrary, no overall association was found for hepatocellular carcinoma. Notably, all studies focusing on colorectal and gastric tumors evaluated LINE-1 methylation in tissue samples, while all the included studies on hepatocellular carcinoma investigated the association only in blood leukocyte samples. Global DNA methylation can be measured by direct and indirect quantification assays. Although the measurement of percentages of 5-methylcytosine to estimate global DNA methylation contents are highly quantitative and reproducible, they require high amount of DNA and are not suitable for large epidemiological studies. Pyrosequencing with bisulfite-treated DNA, the "gold standard" for DNA methylation analysis [67, 68] , is a high-throughput and accurate method currently available to measure LINE-1 methylation as surrogate marker for global DNA hypomethylation. However, LINE-1 methylation levels can vary depending on the target CpG sequence detected [69] , representing an important factor in the association study with cancer risk. In the present meta-analysis, considering the two most frequently used detection methods (pyrosequencing and COBRA LINE-1) both subgroups report significantly lower LINE-1 methylation levels in cancer patients than in control samples, although heterogeneity between studies was significantly high in the pyrosequencing subgroup and moderately high in the COBRA subgroup.
The main limitations of this meta-analysis are the small number of studies included (n = 19) and the high heterogeneity across studies. Although a random effects model was performed, in order to take into account the high heterogeneity, the pooled estimates should be interpreted with caution. To overcome this issue, pooled estimates were calculated in more homogeneous subsets of studies (subgroups analysis). In addition, the possible existence of a publication bias was considered. Examination of funnel plots showed small to moderate asymmetry, suggesting that publication bias cannot be completely excluded and may have had at least a moderate impact on the true effect size estimates. In fact, some data, such as conference abstracts, non-English literature, unpublished data and other inconsistent reports according to our selection criteria were excluded. Furthermore, methylation-risk association tend only to be reported if it reveals statistically significant results, and if the authors deem analysis appropriate [16] .
Moreover, since most studies (83%) had a case-control design large cohort studies are needed in order to clarify if global hypomethylation is an early cancer-causing aberration or an effect of carcinogenesis [11] .
In conclusion, the present meta-analysis adds new evidence to the growing literature on the role of LINE-1 hypomethylation in human cancer and shows that LINE-1 methylation levels were significantly lower in cancer patients than in controls, especially for certain cancer types. This result was confirmed in tissue samples but not in blood. Further studies are needed to better clarify the role of LINE-1 methylation in specific subgroups, considering both the cancer and sample type, and the methods of measurement.
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